

Vivek Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9278490/publications.pdf>

Version: 2024-02-01

76
papers

15,996
citations

430874

18
h-index

128289

60
g-index

78
all docs

78
docs citations

78
times ranked

17905
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
2	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
3	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	7.1	1,691
4	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	13.7	890
5	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	3.5	459
6	The global, regional, and national burden of stomach cancer in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 42-54.	8.1	390
7	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 582-597.	8.1	241
8	The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. <i>Oncologist</i> , 2020, 25, 505-514.	3.7	93
9	<p>The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma<p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 11-17.	3.7	64
10	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2019, 9, 75.	6.2	43
11	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
12	Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. <i>Immunotherapy</i> , 2017, 9, 955-961.	2.0	34
13	Emerging Therapies in the Management of Advanced-Stage Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 404.	3.5	24
14	A Comparative Study of Primary Adenoid Cystic and Mucoepidermoid Carcinoma of Lung. <i>Frontiers in Oncology</i> , 2018, 8, 153.	2.8	23
15	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	6.3	23
16	Unusual Presentation of Metastatic Sebaceous Crcinoma and Its Response to Chemotherapy: Is Genotyping a Right Answer for Guiding Chemotherapy in Rare Tumours?. <i>Current Oncology</i> , 2015, 22, 316-319.	2.2	22
17	Epidemiology and Predictors of all-cause 30-Day readmission in patients with sickle cell crisis. <i>Scientific Reports</i> , 2020, 10, 2082.	3.3	22
18	Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e449-e455.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Clinical course and outcome among patients with acute pancreatitis and COVID-19. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 695-700.	1.6	19
20	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
21	A case series of Kimura's disease: a diagnostic challenge. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 207-211.	2.5	17
22	Primary renal lymphoma: A population-based analysis using the SEER program (1973-2015). <i>European Journal of Haematology</i> , 2020, 104, 390-399.	2.2	16
23	An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. <i>PeerJ</i> , 2018, 6, e4342.	2.0	16
24	Prevalence and characteristics of hereditary non-polyposis colorectal cancer (HNPCC) syndrome in immigrant Asian colorectal cancer patients. <i>BMC Cancer</i> , 2017, 17, 843.	2.6	15
25	Suicide Rates in Cancer Patients in the Current Era in United States. <i>The American Journal of Psychiatry Residents' Journal</i> , 2017, 12, 11-14.	0.3	14
26	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	2.8	14
27	The performance of NLST screening criteria in Asian lung cancer patients. <i>BMC Cancer</i> , 2015, 15, 916.	2.6	13
28	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. <i>JCO Oncology Practice</i> , 2020, 16, e341-e349.	2.9	11
29	Kaposi Sarcoma Mimicking Acute Flare of Ulcerative Colitis. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961771351.	0.6	10
30	Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 576-589.e1.	0.4	10
31	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
32	Intravenous Immunoglobulin-Induced Profound Bradycardia in a Patient With Idiopathic Thrombocytopenic Purpura. <i>American Journal of Therapeutics</i> , 2018, 25, e572-e574.	0.9	9
33	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 435-435.	1.6	9
34	Hereditary angioedema (HAE): a cause for recurrent abdominal pain. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217196.	0.5	8
35	Racial disparities in incidence & survival of Kaposi's sarcoma in the United States. <i>Indian Journal of Medical Research</i> , 2019, 149, 354.	1.0	8
36	Systemic Cystic Angiomatosis Mimicking Metastatic Cancer: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2017, 2017, 1-5.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Changing pattern of secondary cancers among patients with malignant thymoma in the USA. <i>Future Oncology</i> , 2018, 14, 1943-1951.	2.4	7
38	Aortic valve fibroelastoma: a rare cause of stroke. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217631.	0.5	7
39	The pattern of secondary cancers in patients with Kaposi sarcoma in the United States. <i>Cancer Causes and Control</i> , 2017, 28, 1065-1074.	1.8	5
40	Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961769074.	0.6	4
41	Chronic Lymphocytic Leukemia: A Rare Cause of Pathological Fracture of the Femur. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961773513.	0.6	4
42	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
43	Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon \hat{I}^3 Release Assay (IGRA)-Based QuantiFERON Gold Test. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961771754.	0.6	3
44	Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor. <i>American Journal of Therapeutics</i> , 2018, 25, e508-e509.	0.9	3
45	Syndrome of Inappropriate Antidiuretic Hormone Consecutive to treatment with Ciprofloxacin. <i>American Journal of Therapeutics</i> , 2018, 25, e684-e685.	0.9	3
46	Radiation Recall Dermatitis Consecutive to Cabozantinib Use. <i>American Journal of Therapeutics</i> , 2019, 26, e559-e561.	0.9	3
47	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
48	Ataxia in long term survivors of lung cancer after whole brain radiation therapy (WBRT).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20656-e20656.	1.6	3
49	Evaluating the role of massage therapy on patient caregivers in a comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 25-25.	1.6	3
50	Recent Advances in Diffuse Large B Cell Lymphoma. , 2018, , .		2
51	Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis. <i>American Journal of Therapeutics</i> , 2018, 25, e740-e741.	0.9	2
52	Efficacy and safety of primary needle-knife fistulotomy in biliary cannulation. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	1.6	2
53	Penoscrotal haematoma after cardiac catheterisation. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-218934.	0.5	2
54	Challenges to Palliative Care in Pediatric Patients. <i>Journal of Palliative Care & Medicine</i> , 2016, 06, .	0.1	1

#	ARTICLE	IF	CITATIONS
55	Authenticity and Reliability of the Cardiac Monitor Alarms in the ICU: A Patient Safety Concern Due to Alarm Fatigue. <i>Chest</i> , 2017, 152, A566.	0.8	1
56	Prediction of Heparin Induced Thrombocytopenia (HIT) Using a Combination of 4Ts Score and Screening Immune Assays. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096285.	1.7	1
57	Subsequent cancers in the long term survivors of Hodgkin's lymphoma: A SEER based analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19014-e19014.	1.6	1
58	Integration of spiritual care services along with supportive care clinic in a comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2017, 35, 181-181.	1.6	1
59	Secondary Cancers in Hodgkin Lymphoma: A Comprehensive Analysis of Incidence and Trends in Survivors. <i>Blood</i> , 2017, 130, 913-913.	1.4	1
60	A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM). <i>Blood</i> , 2019, 134, 4779-4779.	1.4	1
61	RASMUSSEN ANEURYSM: A RARE CAUSE OF LIFE-THREATENING HEMOPTYSIS. <i>Chest</i> , 2018, 154, 683A.	0.8	0
62	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, 406-406.	1.6	0
63	Primary Cns Lymphoma: Current Diagnosis and Management. <i>Journal of Cancer Prevention & Current Research</i> , 2016, 4, .	0.1	0
64	The incidence, prognosis and survival of primary breast lymphoma: A SEER experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19026-e19026.	1.6	0
65	Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who received neoadjuvant treatment for advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17054-e17054.	1.6	0
66	Risk of Developing Second Cancers in Plasmacytoma in United States. <i>Blood</i> , 2016, 128, 4443-4443.	1.4	0
67	Implementation of an oral chemotherapy adherence tracking program at a medically underserved comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18873-e18873.	1.6	0
68	Oral chemotherapy adherence tracking program implementation at a medically underserved comprehensive community cancer center.. <i>Journal of Clinical Oncology</i> , 2018, 36, 294-294.	1.6	0
69	Trends in the Risk of Second Primary Malignancies (SPMs) Among Survivors of Chronic Lymphocytic Leukemia(CLL). <i>Blood</i> , 2018, 132, 4869-4869.	1.4	0
70	Disparity in Clinical Trial Opportunities for Patients with B-Cell Malignancies in the United States. <i>Blood</i> , 2018, 132, 4861-4861.	1.4	0
71	Trends in the Utilization of Radiation Therapy (XRT) Among Patients with Non-Hodgkin's Lymphoma (NHL) in the United States (US). <i>Blood</i> , 2018, 132, 4765-4765.	1.4	0
72	Timeliness of Initial Therapy in Multiple Myeloma (MM): Trends and Factors Influencing Patient Care. <i>Blood</i> , 2018, 132, 4764-4764.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Sociodemographic Profile and Outcomes of Patients with Non-Diffuse Large B-Cell Lymphoma (non-DLBCL) Treated at Minority-Predominant Facilities in the United States. <i>Blood</i> , 2018, 132, 4868-4868.	1.4	0
74	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16037-e16037.	1.6	0
75	Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 201-212.	2.3	0
76	Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes. <i>Blood</i> , 2019, 134, 3494-3494.	1.4	0